Hypofractionated radiotherapy boost in prostate cancer
Phase 1
Completed
- Conditions
- Health Condition 1: null- Prostate cancer
- Registration Number
- CTRI/2018/07/014948
- Lead Sponsor
- Department of radiotherapy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 15
Inclusion Criteria
1.Previously untreated biopsy proven prostate adenocarcinoma.
2.Localized carcinoma prostate (Stage T1 T2 T3) as per TNM staging system.
3.Karnofsky performance scale (KPS) > 70
4.Normal Hemogram, renal and liver function.
5.Informed consent for participation in the study
Exclusion Criteria
1.Carcinoma prostate other than adenocarcinoma histology.
2.Stage T4
3.Lymph nodal involvement N+
4.Evidence of distant metastasis on chest X â?? ray or Bone Scan.
5.Patients having any uncontrolled co-morbid conditions.
6.Prior pelvic radiotherapy
7.Presence of 2nd malignancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.To assess the acute toxicity occurring with treatment with IMRT followed by SBRT boost in localized prostate cancerTimepoint: Toxicities are assessed -- <br/ ><br>a)weekly during radiotherapy treatment <br/ ><br>b)at the end of first,second and third months of radiotherapy completion
- Secondary Outcome Measures
Name Time Method 2.To evaluate the improvement or decline in urinary function with treatment. <br/ ><br>3.To study the short-term treatment outcome on radiological basis. <br/ ><br>Timepoint: urinary function assesed weekly during treatment and 1st and 3rd month post treatment <br/ ><br>treatment response assessed post 3 months of treatment